FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092312956> ?p ?o ?g. }

• W3092312956 abstract "The mechanisms of trained immunity have been extensively described in vitro and the beneficial effects are starting to be deciphered in in vivo settings. Prototypical compounds inducing trained immunity, such as β-glucans, act through epigenetic reprogramming and metabolic changes of innate immune cells. The recent advances in this field have opened new areas for the development of Trained Immunity-based Adjuvants (TIbA). In this study, we assessed in dogs the potential immune training effects of β-glucans as well as their capacity to enhance the adaptive immune response of an inactivated rabies vaccine (Rabisin®). Injection of β-glucan from Euglena gracilis was performed one month before vaccination with Rabisin® supplemented or not with the same β-glucan used as adjuvant. Trained innate immunity parameters were assessed during the first month of the trial. The second phase of the study was focused on the ability of β-glucan to enhance adaptive immune responses measured by multiple immunological parameters. B and T-cell specific responses were monitored to evaluate the immunogenicity of the rabies vaccine adjuvanted with β-glucan or not. Our preliminary results support that adjuvantation of Rabisin® vaccine with β-glucan elicit a higher B-lymphocyte immune response, the prevailing factor of protection against rabies. β-glucan also tend to stimulate the T cell response as shown by the cytokine secretion profile of PBMCs re-stimulated ex vivo. The potential of TIbA to provide increased immunogenicity of specific vaccines while conferring broad non-specific responses is only starting to be investigated. Our data are providing new insights on the impact of trained immunity on the adaptive immune response to vaccines in dogs. The administration of β-glucan, one month before or simultaneously to Rabisin® vaccination give promising results for the generation of new TIbA candidates. In the context of finding new approaches to vaccine design, trained immunity-based adjuvants could trigger a broad innate response to unrelated or bystander pathogens and a specific response to vaccines." @default.
• W3092312956 created "2020-10-15" @default.
• W3092312956 creator A5005722278 @default.
• W3092312956 creator A5022176360 @default.
• W3092312956 creator A5045491980 @default.
• W3092312956 creator A5051267468 @default.
• W3092312956 creator A5054575232 @default.
• W3092312956 creator A5055599983 @default.
• W3092312956 creator A5055870060 @default.
• W3092312956 creator A5070999859 @default.
• W3092312956 creator A5071684217 @default.
• W3092312956 creator A5073972158 @default.
• W3092312956 creator A5082135168 @default.
• W3092312956 date "2020-10-08" @default.
• W3092312956 modified "2023-10-10" @default.
• W3092312956 title "β-Glucan as Trained Immunity-Based Adjuvants for Rabies Vaccines in Dogs" @default.
• W3092312956 cites W1566992315 @default.
• W3092312956 cites W1591131153 @default.
• W3092312956 cites W1774768800 @default.
• W3092312956 cites W1837022211 @default.
• W3092312956 cites W1839141223 @default.
• W3092312956 cites W1936109457 @default.
• W3092312956 cites W1972452655 @default.
• W3092312956 cites W1984281825 @default.
• W3092312956 cites W1989800280 @default.
• W3092312956 cites W1989888538 @default.
• W3092312956 cites W1989975765 @default.
• W3092312956 cites W2013874327 @default.
• W3092312956 cites W2018261122 @default.
• W3092312956 cites W2022846836 @default.
• W3092312956 cites W2043345501 @default.
• W3092312956 cites W2047526240 @default.
• W3092312956 cites W2059403792 @default.
• W3092312956 cites W2089421858 @default.
• W3092312956 cites W2114749317 @default.
• W3092312956 cites W2128337342 @default.
• W3092312956 cites W2128489214 @default.
• W3092312956 cites W2143168086 @default.
• W3092312956 cites W2159560463 @default.
• W3092312956 cites W2232762837 @default.
• W3092312956 cites W2288992930 @default.
• W3092312956 cites W2336656712 @default.
• W3092312956 cites W2544042101 @default.
• W3092312956 cites W2589917023 @default.
• W3092312956 cites W2597008625 @default.
• W3092312956 cites W2618437552 @default.
• W3092312956 cites W2621836279 @default.
• W3092312956 cites W2626215747 @default.
• W3092312956 cites W2724154348 @default.
• W3092312956 cites W2756142265 @default.
• W3092312956 cites W2771968994 @default.
• W3092312956 cites W2783037826 @default.
• W3092312956 cites W2783642412 @default.
• W3092312956 cites W2895418972 @default.
• W3092312956 cites W2895493756 @default.
• W3092312956 cites W2900474461 @default.
• W3092312956 cites W2902546561 @default.
• W3092312956 cites W2905235893 @default.
• W3092312956 cites W2914628008 @default.
• W3092312956 cites W2940394837 @default.
• W3092312956 cites W2945172731 @default.
• W3092312956 cites W2945350042 @default.
• W3092312956 cites W2971960535 @default.
• W3092312956 cites W2983356737 @default.
• W3092312956 cites W2990092235 @default.
• W3092312956 cites W2994649468 @default.
• W3092312956 cites W2997792277 @default.
• W3092312956 cites W2998293467 @default.
• W3092312956 cites W3000675627 @default.
• W3092312956 cites W3000690472 @default.
• W3092312956 cites W3001051278 @default.
• W3092312956 cites W3003683184 @default.
• W3092312956 cites W3009920944 @default.
• W3092312956 doi "https://doi.org/10.3389/fimmu.2020.564497" @default.
• W3092312956 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7580252" @default.
• W3092312956 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33162977" @default.
• W3092312956 hasPublicationYear "2020" @default.
• W3092312956 type Work @default.
• W3092312956 sameAs 3092312956 @default.
• W3092312956 citedByCount "12" @default.
• W3092312956 countsByYear W30923129562021 @default.
• W3092312956 countsByYear W30923129562022 @default.
• W3092312956 countsByYear W30923129562023 @default.
• W3092312956 crossrefType "journal-article" @default.
• W3092312956 hasAuthorship W3092312956A5005722278 @default.
• W3092312956 hasAuthorship W3092312956A5022176360 @default.
• W3092312956 hasAuthorship W3092312956A5045491980 @default.
• W3092312956 hasAuthorship W3092312956A5051267468 @default.
• W3092312956 hasAuthorship W3092312956A5054575232 @default.
• W3092312956 hasAuthorship W3092312956A5055599983 @default.
• W3092312956 hasAuthorship W3092312956A5055870060 @default.
• W3092312956 hasAuthorship W3092312956A5070999859 @default.
• W3092312956 hasAuthorship W3092312956A5071684217 @default.
• W3092312956 hasAuthorship W3092312956A5073972158 @default.
• W3092312956 hasAuthorship W3092312956A5082135168 @default.
• W3092312956 hasBestOaLocation W30923129561 @default.
• W3092312956 hasConcept C136449434 @default.
• W3092312956 hasConcept C159654299 @default.
• W3092312956 hasConcept C193419808 @default.
• W3092312956 hasConcept C203014093 @default.

• next